DBVTF
What one share of DBV Technologies S.A. holds
Biological Products, (No Diagnostic Substances)
DBV Technologies is a late-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. Our therapeutic approach is based on epicutaneous immunotherapy, or EPIT, our proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch).
DBV Technologies S.A.’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.02 |
|---|---|
| Profit | −$0.60 |
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$0.58 |
| Cash and investments | $0.59 |
| Book value | $0.54 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2019 | $0.40 | −$4.65 | $0.15 | −$4.16 | — | $4.11 |
| 2020 | $0.21 | −$2.95 | $0.05 | −$3.11 | — | $3.80 |
| 2021 | $0.10 | −$1.78 | $0.02 | −$1.99 | — | $1.80 |
| 2022 | $0.06 | −$1.24 | $0.01 | −$0.73 | — | $2.07 |
| 2023 | $0.17 | −$0.76 | $0.01 | −$0.84 | — | $1.45 |
| 2024 | $0.04 | −$1.17 | $0.02 | −$1.10 | — | $0.27 |
| 2025 | $0.04 | −$1.05 | $0.00 | −$0.87 | — | $0.57 |